Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Cited In for PubMed (Select 11279501)

1.

Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Schneider H, Rudd CE.

Front Immunol. 2014 Dec 4;5:619. doi: 10.3389/fimmu.2014.00619. eCollection 2014. Review.

2.

Structure and cancer immunotherapy of the B7 family member B7x.

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X.

Cell Rep. 2014 Nov 6;9(3):1089-98. doi: 10.1016/j.celrep.2014.09.053. Epub 2014 Oct 30.

3.

Structural basis for recognition of cellular and viral ligands by NK cell receptors.

Li Y, Mariuzza RA.

Front Immunol. 2014 Mar 26;5:123. doi: 10.3389/fimmu.2014.00123. eCollection 2014. Review.

4.

T cell receptor signaling can directly enhance the avidity of CD28 ligand binding.

Sanchez-Lockhart M, Rojas AV, Fettis MM, Bauserman R, Higa TR, Miao H, Waugh RE, Miller J.

PLoS One. 2014 Feb 24;9(2):e89263. doi: 10.1371/journal.pone.0089263. eCollection 2014.

5.

CD28: direct and critical receptor for superantigen toxins.

Kaempfer R, Arad G, Levy R, Hillman D, Nasie I, Rotfogel Z.

Toxins (Basel). 2013 Sep 9;5(9):1531-42. doi: 10.3390/toxins5091531. Review.

6.

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84. doi: 10.1073/pnas.1303524110. Epub 2013 May 28.

7.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

8.

Structure and T cell inhibition properties of B7 family member, B7-H3.

Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC.

Structure. 2013 May 7;21(5):707-17. doi: 10.1016/j.str.2013.03.003. Epub 2013 Apr 11.

9.

Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.

Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, Chen H, Phung S, Muchhal US, Horton HM, Lazar GA, Desjarlais JR, Szymkowski DE.

MAbs. 2013 May-Jun;5(3):384-96. doi: 10.4161/mabs.23976. Epub 2013 Apr 2.

10.

Structural insights into activation of antiviral NK cell responses.

Finton KA, Strong RK.

Immunol Rev. 2012 Nov;250(1):239-57. doi: 10.1111/j.1600-065X.2012.01168.x. Review.

11.

Nectin ectodomain structures reveal a canonical adhesive interface.

Harrison OJ, Vendome J, Brasch J, Jin X, Hong S, Katsamba PS, Ahlsen G, Troyanovsky RB, Troyanovsky SM, Honig B, Shapiro L.

Nat Struct Mol Biol. 2012 Sep;19(9):906-15. doi: 10.1038/nsmb.2366. Epub 2012 Aug 19.

12.

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL, Grogan JL.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5399-404. doi: 10.1073/pnas.1120606109. Epub 2012 Mar 15.

13.

Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.

Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, Supper E, Shpilka T, Minis A, Kaempfer R.

PLoS Biol. 2011 Sep;9(9):e1001149. doi: 10.1371/journal.pbio.1001149. Epub 2011 Sep 13.

14.

Use of the α-mannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells.

Yu C, Crispin M, Sonnen AF, Harvey DJ, Chang VT, Evans EJ, Scanlan CN, Stuart DI, Gilbert RJ, Davis SJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Jul 1;67(Pt 7):785-9. doi: 10.1107/S1744309111017672. Epub 2011 Jun 30.

15.

B7-h2 is a costimulatory ligand for CD28 in human.

Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, Broadwater M, Ruff W, Flies S, Xu H, Flies D, Luo L, Wang S, Chen L.

Immunity. 2011 May 27;34(5):729-40. doi: 10.1016/j.immuni.2011.03.014. Epub 2011 Apr 28.

16.

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA.

Immunol Rev. 2011 May;241(1):180-205. doi: 10.1111/j.1600-065X.2011.01011.x. Review.

17.

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site.

Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6223-8. doi: 10.1073/pnas.1100622108. Epub 2011 Mar 28.

18.

Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.

Li Y, Wang Q, Mariuzza RA.

J Exp Med. 2011 Apr 11;208(4):703-14. doi: 10.1084/jem.20102548. Epub 2011 Mar 21.

19.

Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.

Yu C, Sonnen AF, George R, Dessailly BH, Stagg LJ, Evans EJ, Orengo CA, Stuart DI, Ladbury JE, Ikemizu S, Gilbert RJ, Davis SJ.

J Biol Chem. 2011 Feb 25;286(8):6685-96. doi: 10.1074/jbc.M110.182394. Epub 2010 Dec 14.

20.

Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor.

Radaev S, Zou Z, Tolar P, Nguyen K, Nguyen A, Krueger PD, Stutzman N, Pierce S, Sun PD.

Structure. 2010 Aug 11;18(8):934-43. doi: 10.1016/j.str.2010.04.019.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk